Get Ready for Hot Sub-Penny Momo Play coming to you tomorrow morning right at the opening bell.

‘SPO’ has joined in with at least 10 groups to bring you a Non-Compensated Momo Play that will be released tomorrow morning right at 9:30 eastern time, and it should be a lot of fun and profitable at the same time.

Best of luck in your Trading,
The SPO Crew www.stockplaysonline.com/visichat

Premiere Opportunities Group, Inc. Signs Agreement With Flex Fuel Technologies, Inc. and Sets Definitive Date for Closing Its Merger With Global Products, Inc.
TOTOWA, NJ, May 17, 2012 (MARKETWIRE via COMTEX) — Premiere Opportunities Group, Inc. (otcqb:PPBL) /quotes/zigman/5675852/quotes/nls/ppbl PPBL +23.33% ( www.premiereopportunities.com ) has signed an advisory agreement with Flex Fuel Technologies Inc. ( www.flexfueltech.com ) to assist the company with its strategic planning, EPA testing and budget planning for the future introduction of its products into the automotive aftermarket.

Flex Fuel Technologies, Inc., after several years of testing, has developed a " bolt on technology" that allows most four, six and eight cylinder cars to run on both E85 (ethanol) as well as gasoline at a fraction of the cost that a buyer would pay at the OEM/Dealer level for the flex fuel option on a new vehicle.

The product known as Flex Genie (TM) will begin its EPA testing in the mid-summer and expect to be completed with that testing by the end of 2012. If the results are as expected, Flex Fuel Technologies will begin the commercialization process of this breakthrough product immediately thereafter. It is expected that the Flex Genie will be priced at well under $1000, installed and be distributed in both retail stores as well as other distribution channels.

The Company will also assist Flex Fuel Technologies, Inc. with its other goal of becoming a public company and expects the Company to file its registration statement with the Securities and Exchange Commission this coming June.

The Company is also happy to announce that it has set May 29th as the definitive closing date for Premiere’s merger with Global Products, Inc.

Upon the consummation of the merger with Global Premiere, shareholders will own shares not only in Global Products, Inc., but also retain shares in our other client companies, including but not limited to Luminx Holdings, Defense Technologies Corp., Flex Fuel Technologies Inc. and Trident Equity Advisors Inc., all of which will file separate registration statements with the Securities and Exchange Commission to become stand-alone public companies.

The Company looks forward to the future with great enthusiasm and expects it to be filled with opportunity for Premiere shareholders as the Company continues to make our reputation stronger by virtue of the services it delivers to our client companies and the value it creates for our shareholders.

Contact:
Chris Giordano
973-390-0072

SOURCE: Premiere Publishing Group, Inc

A First Quarter of resounding success for Papa Bello Enterprises PAPA

Today : Wednesday 16 May 2012

Papa Bello Enterprises (Pink Sheets: PAPA) discusses its success in the first quarter of 2012.

It has been a productive 1st quarter for Papa Bello Enterprises. As winter turned into spring, and as school comes to an end for the 2011-2012 year, we would like to take stock of how we have moved forward with our company in the first quarter of 2012.

One of the most important items to talk about in the first quarter of 2012 is the acquisition of Mama’s Direct, Inc. (MDI). The goal of MDI has always been to "Revolutionize how and what we eat." Everyone needs to eat and not everyone has time to cook healthy, delicious meals.

MDI will use a Direct Sales business methodology for distribution as well as retail facilities in major metropolitan cities. These facilities will include a bistro, retail sales for customers, and a meeting place for our direct sales teams.

Our initial efforts have been a resounding success.

In the first quarter, we met with thousands of potential customers by sponsoring events, inviting celebrities to try out the fare, and through our friends and family network.

If I had to sum up our responses in one word … "Unbelievable." We have cooked for three hundred people in just a few minutes, and when we tell folks how we prepared the food. They’re hooked. The technology and food brought to the table by Mama’s Direct will revolutionize cooking.

In the first quarter, we not only launched Mama’s Direct, but we acquired funding for our upcoming growth. $20,000,000 worth of funding was put into place with AGS capital. This funding allows the company to grow on its terms without undue strain on shareholders. It also gives the company the necessary funds to handle what we will expect will be a parabolic curve of growth.

Starting a company with the probability of explosive growth like Papa Bello needs experienced men at the helm. We brought in The Bull Consulting Group, a company with over fifteen years of experience in the markets to help build our funding portfolio, establish an east coast presence, create introductions into outlets that are providing sporting icons to work with the company and promote food distribution, and put into place a world-class organizational structure.

We cannot build a strong company without a strong base of support, which is why it was so important to us to become current on the pink sheets, and acquire a facility that could accommodate our growth. In April we became ‘Current’ and will follow up this success with future uplist and immediately following that, we announced an 80,000 square foot facility in Yorba Linda California. We expect that this new corporate headquarters building will be able to contain our growth for the remainder of 2012, but we will be looking at other facilities across the nation as we grow.

Our corporate goal was to launch a number of organizations that would move the needle across the food, marketing and advertising industries. Our goal is to create a better distribution model, sales process, healthier lifestyle, and allow consumers to customize their shopping experience, while improving sales for partner companies.

We’re moving on through 2012 with three major brands.
•Mama’s Direct, Inc.
•Blow me Away Media
•Limited Edition Ink

Each of these brands, by itself can be a powerful company. All three together will be explosive.

Mama’s Direct is about to become a household name across the United States. Those selling the products are consumers who love the products and have chosen to sell the product. We have successfully turned skeptics into supporters as we have travelled around, and as we build the base of this direct sales business, our goal is to be on the tip of the tongue of hundreds of thousands of consumers.

In closing out our first quarter, we found our way into the hearts and minds of Hollywood celebrities. A number of high-powered Hollywood stars have sampled and have signed on with the Mama’s Direct Brand. As soon as we can disclose these names across sports, entertainment, and theater, we will.

The second quarter of 2012 will find us sponsoring some huge events that we will announce soon, and we will officially launch "The Summer of Food Delivery."

We expect to file our S1 as soon as we are able, and we will update shareholders on all of our exciting progress as it falls into place.

About Papa Bello Enterprises

Founded in 2005, and based in Yorba Linda, CA, Papa Bello Enterprises (PAPA.PK) owns and operates a diversified group of companies as majority owned subsidiaries. In addition, Papa provides expansion tools and operational support services to growth-stage businesses. The company was founded on the principles of providing the consumer with the highest standards of quality, value, and service. Additional information may be found at http://www.pbe.us.com

Forward-Looking Statements Disclosure ?This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risks, and uncertainties, and by reference to the underlying assumptions.

Contact: ?Jim Wheeler ?Papa Bello Enterprises ?Yorba Linda, CA ?(888) 641-2626

We have come across a stock that could very well be ready for a Huge Bounce Play and want you to take a close look at it.

STKO- Stakool, Inc.

STKO Released some exciting news yesterday after the markets closed and if you combine that with the way the chart is setting up, we could have a real winner here. We suggest you get STKO on your radar/watch lists right away and let’s see how this plays out.

Stakool/Anthus Life Corp. Sales Gaining Momentum

Natural plus Energy(TM) Is Successful at All Recent Accounts

JACKSONVILLE, FL–(Marketwire -05/15/12)- Stakool Inc. (STKO.OB) (OTC.BB: STKO), a Florida-based corporation, is pleased to announce that its wholly-owned subsidiary, Anthus Life Corp.’s product line is finding success with all recent accounts.

Le Gourmet Chef stores throughout the US are in receipt of their initial stock. All indications are that the product in its first month is doing very well, and that additional orders will be forthcoming.

The relationship with Red Rock Resorts and its catering operation continues to prosper. Since the relationship began in mid-September 2011, six orders have been placed. Currently, Red Rock Resorts is on track to place monthly orders.

The utilization of alice.com’s direct-consumer platform for the consumer packaged goods industry is also showing signs of increased growth. Once the brand gains a greater degree of awareness, significant growth could be realized via this channel.

Peter Hellwig, President & CEO of Stakool and Anthus Life, states, "We are very satisfied with the progress over the last few months. We receive calls from individual consumers looking for our products after they have come in contact with them at a convention in Red Rock Resorts, and now we have national retailer to point them to, or they can easily source them online. So, the initial steps have been successful and additional awareness, as well as the previously announced repackaging will result in continued success." Mr. Hellwig, also states that, "as a result of the recent arrangement with Ironridge, we will soon be able to capitalize on implementing programs for branding and awareness — making the outlook for the balance of 2012 very exciting."

You can also read all of the latest News & Filings from STKO at the following SPO Forum: http://www.stockplaysonline.com/penn…akool-inc.html

We will update you with any new developments as they become available.

Best of luck in your Trading,
The SPO Crew www.stockplaysonline.com/visichat

(disclaimer applies)

Stakool/Anthus Life Corp. to Introduce New Packaging

Natural plus Energy Packaging Will Better Serve Retail and Consumer

JACKSONVILLE, FL–(Marketwire -04/16/12)- Stakool, Inc. (OTCQB: STKO.OB – News) (OTC.BB: STKO.OB – News), a Florida-based corporation, is pleased to announce that its wholly-owned subsidiary Anthus Life Corp. is in the final stages of repackaging its Natural plus Energy product and plans to introduce its new packaging within the next 45 days.

The new Natural plus Energy packaging will better serve the current and changing needs of retailers. As the Company expands from its niche and boutique retail origins, and gains footholds with national distributors and retailers, the packaging design will be better received by larger retailers and their consumers. The Company is also working on finalizing its Kosher certification, which is important for greater market penetration in the domestic market, and imperative for the export market. In addition, the display box will carry the Shannon Miller, 7-time Olympic medalist, endorsement.

Peter Hellwig, President & CEO of Stakool and Anthus Life, states, "Going through this redesign process has been exciting. When we first started out, the need to depict that your product was gluten free or trans fat free or all natural, was not so important. Now, however, retailers are implementing gluten free and all natural planograms, and consumers are actively looking for products that are specifically gluten free, dairy free, all natural, and so on. It became imperative for us to highlight all of the true benefits of our product. We are sure that the new packaging will assist in increasing volume and attracting new retailers and consumers alike." Mr. Hellwig goes on to state, "Incorporating the Shannon Miller endorsement will be a key factor, for general visibility, as well as capitalizing on the fact that 2012 is an Olympic year."

15-May-2012

Quarterly Report

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

FORWARD-LOOKING STATEMENTS
This discussion and analysis in this Quarterly Report on Form 10-Q should be read in conjunction with the accompanying unaudited Financial Statements and related notes for the three months ended March 31, 2011 and 2010 and for the period from December 23, 1999 to March 31, 2012. Our discussion and analysis of our financial condition and results of operations are based upon our unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. We review our estimates and assumptions on an on-going basis. Our estimates are based on our historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Our critical accounting policies, the policies we believe are most important to the presentation of our financial statements and require the most difficult, subjective and complex judgments, are outlined below in ”Critical Accounting Policies,” and have not changed significantly.

In addition, certain statements made in this report may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Specifically, but not limited to, 1) our ability to obtain necessary regulatory approvals for our products; and 2) our ability to increase revenues and operating income, is dependent upon our ability to develop and sell our products, general economic conditions, and other factors. You can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continues" or the negative of these terms or other comparable terminology. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. Although we believe that the expectations reflected-in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Forward-looking statements are only predictions. The forward-looking events discussed in this Quarterly Report, the documents to which we refer you, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. For these statements, we claim the protection of the "bespeaks caution" doctrine. The forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation to publicly release the results of any revisions to these forward-looking statements to reflect events or circumstances after the date of this filing.

Critical Accounting Policies

Our critical and significant accounting policies, including the assumptions and judgments underlying them, are disclosed in the Notes to the Financial Statements. These policies have been consistently applied in all material respects. The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. See our audited financial statements and notes thereto which contain accounting policies and other disclosures required by accounting principles, generally accepted in the United States of America.

——————————————————————————–

Important Disclosures and Disclaimers.
Please note that ProtoKinetix, Inc. (the "Company") is a research and product development stage company that has not yet sold any products. The Company had $0 in revenues for the Period ending March 31, 2012.

It is important to understand that although the Company (as is discussed below) is focused on various promising scientific and business development efforts, to date, we have not yet marketed a product. Ongoing testing of the AAGP� molecule with three amino acids joined to a monosaccharide by a gemdifluride bond continues to show that there is significant promise in the field of medicine of preserving cells, tissue and organs from various stresses. The antiaging properties and the protective effect of AAGP� also is of significant interest to the cosmetic and skin care industries. Tests have confirmed that the AAGP� molecule improves the harvest of cells from cryopreservation by 30% to 120%. We believe there is a market for AAGP� to preserve cells, particularly various stem cells, and we will continue testing with potential customers. At the same time we are taking steps to improve the manufacturing process to reduce costs and improve purity and biochemical activity.

Our progress to date has been achieved notwithstanding the inherent risks relating to the science, applications, market opportunities and commercial relationships. The progress of the business has and will continue to be dependant on having appropriate human and sufficient financial resources which have and will be uncertain.

Overview

ProtoKinetix owns the world-wide rights to a family of anti-aging glycopeptides, trademarked as AAGPs�. In scientific studies and tests AAGPs� have demonstrated the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to severe stress conditions under laboratory controlled test conditions. AAGPs� are stable and non-toxic.

Since 2005, ProtoKinetix has primarily focused on scientific research, however recently the company has been in the process of directing major efforts to the practical side of commercial validation and product development initiatives, particularly in regenerative medicine and the preservation of stem cells and other biological products and tools used in medical applications. The commercial applications for AAGPs� in large markets such as skincare/cosmetic products and targeted health care solutions are numerous. ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP� to market.

Native AFGP Compound

AFGP (Anti-Freeze Glycoprotein) is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures.

One of the many accomplishments from pioneering research of the U.S. Antarctic Program was the discovery, in the early sixties, that fish living year-long in subzero temperature are extremely resistant to freezing. The substances that prevent these fish from freezing were isolated, characterized and designated as antifreeze glycoproteins or AFGP. Various kinds of AFGP were isolated from many species of fishes, and in some amphibians, plants and insects. All of the AFGPs share a common characteristic that prevents ice crystals from growing and connecting to each other. Research has also confirmed a cell membrane stabilizing characteristics of native AFGP.

There has been much scientific research done in an attempt to synthetically replicate AFGPs in research institutions because the protective properties of AFGPs could have commercial applications, primarily in food and crop preservation at freezing temperatures. The native antifreeze glycoproteins are very large molecules that are often made up of a repeating series of smaller molecules, glycoproteins. Glycoproteins are often very biologically active, but they are inherently quite unstable. The oxygen-glycosidic link is readily cleaved by glycosidases, resulting in a low bio-availability of these glycoconjugate based molecules.

Scientific research prior to AAGP has focused on building a stable and more efficient compound with a strong bond.

——————————————————————————–
AAGP� – The Core Technology of ProtoKinetix
AAGP� Invention

Dr. Geraldine Castelot-Deliencourt, along with Dr. Jean-Charles Quirion at the Research Institute of Organic Chemistry in Rouen, France, developed a patented process to stabilize the oxygen-glycosidic bond in these sugar based molecules. This patented process replaces the weaker oxygen bond with a C-F2 mimetic. The resultant molecules are biologically active and stable over a pH range of 2 to 13. They are not broken down by glycosidases.

AAGP� Toxicity Tests

Tests have shown cells that have been exposed to AAGP� at low and high concentrations have remained viable. A common viability test used on cell cultures using trypan blue dye exclusion method has been used to show AAGP� non-toxicity.

AAGP� Stability Tests

AAGP� molecules have remained stable when subjected to three tests:

1. pH ranging from a strong acid level of 1.8 (stronger than stomach acid) to a strong alkali level of 13.8. (the pH scale is calibrated from 1, highly acidic, to 14, highly alkali);

2. Enzymatic action using protease, which targets the amino acid bonds, and glycosidase, which targets the amino acid bonds, and glycosidase, which targets the sugar molecules; and

3. Temperatures ranging from -196�C (cryopreservation) to +37�C (body temperature).

Stress Tests on 12 Different Cell Lines

Cell lines are selected for their high level of sensitivity. Cell lines are
also selected for their potential role in adding value in medical applications,
enhancing health and extending life. All tests are designed to explore how cells
from different cell lines act biologically in the presence of AAGP� when
subjected to health and life threatening inflammatory stress conditions and
agents.

Cell Lines Tested

Stem cells (human) Adult skin fibroblast cells
Whole blood cells Heart cells (cardiac myocites)
Blood Platelet cells Liver cells (hepatocites)
Heart tissue Embryonic skin fibroblast cells
Hela (cancer) cells Islet cells (pancreatic)
Kidney (KB and vero) cells Stem cells (mouse)

Stress Conditions and Agents

Temperature

� temperatures ranging from -80� C to +37�

UV-C Radiation

� harsh sterilizing radiation
� 254 nanometer wavelength

Oxidation

� hydrogen peroxide (H2O20
� powerful oxidant

——————————————————————————–
Starvation
� serum free culture media
� food/growth/nutrients factors (fetal bovine serum) withheld

Inflammation

� Interleukin 1 Beta, a standard agent for stimulating inflammation in cell testing
� All of the above tests are also considered to cause inflammation

Bio-Screening Control Lab Testing

AAGP� testing is conducted to international standards in outsourced research laboratories in North America and Europe. All tests are designed to explore both the safety and effectiveness of AAGP� when challenged to enhance the health and extend the life of cells.

Test Results Summary

Cells that were tested in the presence of AAGP� had a higher survival and viability rate than the controls. The overall effect of AAGP� is to protect, preserve and in some cases to repair. Anti-inflammatory effects appear to be at work, although the mechanism and pathways of action are not yet determined. AAGP� appears to enhance heath and extend cell life.

The test results are considered preliminary. The limited number of samples and extent of the tests are designed to investigate the potential attributes of AAGP� and should not be considered as statistically or scientifically conclusive. Notwithstanding, we feel the results are sufficient to justify further tests by commercial entities in health care.

AAGP� Commercial Applications

The extent of the value of the ProtoKinetix family of AAGPs� is being investigated by companies and the Company is targeting commercial entities specializing in regenerative medicine, cellular and tissue therapies, organ transplantation, trauma, blood product banking, anti- inflammation and cosmetics/skin care.

Skincare and Cosmetics

Industry sources estimate that the skincare market in the USA, including both mass and prestige, will reach $7.2 billion by 2010, driven in part by expected double-digit growth of anti-aging products, which is likely to become the second largest category behind hand & body lotions in the industry.

According to the Johnson and Johnson 2003 Annual Report, the global skin care and cosmetics market is already running easily in the tens of billions at some $43 billion dollars per year.

In the skin care business it’s about healthier, younger looking skin. The two major causes of dry, wrinkled, less elastic or even diseased skin are inflammation and oxidation. The main culprits are the sun (UV rays and free radicals) and other environmental and physiological stresses that also cause inflammation and oxidation.

When AAGP� is combined with Coenzyme Q10 a powerful anti-oxidant effect is achieved that not only protects but also seems to help the cells repair previously existing damage. In vitro laboratory tests have shown the AAGP� molecules can protect in vitro skin cells from damage and death that would otherwise occur from UV rays and free radicals. To the extent of the laboratory tests conducted, AAGP� appears to protect in vitro skin cells from cold temperatures, oxidation, UV irradiation and pH variations.

——————————————————————————–
Health Care
Acute medical problems are increasingly reliant on, and benefit from, solutions that can deal with the fundamental factors of inflammation and oxidation. Both are well-known causes of life-threatening conditions and diseases, and accelerated aging. In addition many acute medical problems are benefiting from cell therapies and transplantation of cells, tissues and time sensitive organs.

Health Care Applications of AAGP� fall into two main categories: (i) harvesting, storage and transplanting cells, tissues and organs; and (ii) treatments for conditions and disease caused by stress factors, including UV radiation, oxidation and inflammation. These are all areas that expand into many sub-categories of existing and future health care solutions.

Intellectual Property

Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection. Our commercial success will depend in part on maintaining patent protection and trade secret protection for our products, as well as successfully defending these patents against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.

The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.

Patents

As of the date of this Report, our development agents, including the parties we have licensed AAGP� technologies from, have applied to receive patents for technologies we have licensed and continue to primarily base our research efforts on. At present, we have engaged the patent law firm of Cabinet-Moutard of Versaille, France, and have filed a number of international patent applications. These patent applications include:

WO 2004/014928 A2 (19 February 2004)
PCT Int. Appl. (2006), 87 pp. WO2006059227 A1 20060608 AN 2006:538719 Patent application: Fr 03 May 2006, 06 03952

Consistent with our agreements with the licensors of various technologies we license, we have no finished commercial product or products, and have received no final patents awards or FDA approvals for any product or diagnostic procedures. We are focused on the research and development of one primary compound known as AAGP�, which we have filed a trademark application for.

Subject to our available financial resources, our intellectual property strategy is: (1) to pursue licenses, trade secrets, and know-how within our primary research areas, and (2) to develop and acquire proprietary positions to reagents and new platforms for the development of products related to these technologies.

——————————————————————————–
Trade Secrets and Know-How
We have developed a substantial body of trade secrets and know-how relating to the development, use and manufacture of AAGP�, including but not limited to the optimization of materials for efforts, and how to maximize sensitivity, speed-to-result, specificity, stability, purity and reproducibility.

Super Antibody and Catalytic Antibody Platform Technologies

We continue to own the rights to both the Super Antibody and the Catalytic Antibody platform technologies. We plan to, as a secondary priority and subject to available resources, search for a patentable receptor sites that exist on cancer cells.

Competition

The markets that we are focusing on are multi-billion dollar international industries. They are intensely competitive. Many of our competitors are substantially larger and have greater financial, research, manufacturing, and marketing resources.

Industry competition in general is based on the following:

� Scientific and technological capability;
� Proprietary know-how;
� The ability to develop and market products and processes;
� The ability to obtain FDA or other required regulatory approvals;
� The ability to manufacture products that meet applicable FDA requirements, (i.e. FDA’s Quality System Regulations) see Governmental Regulation section;
� Access to adequate capital;
� The ability to attract and retain qualified personnel; and
� The availability of patent protection.

We believe our scientific and technological capabilities are significant.

Our ability to develop our research is in large measure dependent on having sufficient and additional resources and/or collaborative relationships.

Our access to capital is more challenging, relative to most of our competitors. This is a competitive disadvantage. We believe however that our access to capital may increase as we get closer to the development of a commercially viable product.

We believe that our research has enabled us to attract and retain qualified consultants. Because of the greater financial resources of many of our competitors, we may not be able to complete effectively for the same individuals to the extent that a competitor uses its substantial resources to attract any such individuals.

Employees

We currently have no full time employees. We operate with a skeletal management team of consultants headed by our Chief Executive Officer Ross Senior. In addition, we receive advice and counsel from our Business and Scientific Advisory Board.

Governmental Regulation

Our AAGPs� have commercial applications in markets and circumstances that fall under government regulations ranging from none to limited to extensive.

Although there is no such immediate need to make any regulatory filing in the United States or other jurisdictions, we have limited or no experience with regard to obtaining FDA or other required regulatory approvals. We intend to retain the services of appropriately experiences consultants. For this reason, should our research efforts continue to show promise, we will need to hire consultants to assist the Company with such governmental regulations.

——————————————————————————–
As we continue to conduct research and testing programs, in collaboration with commercial entities, to expand and confirm the potential medical applications of AAGP� in the a number of fields, including regenerative medicine, cell therapy, blood products, transplants and skin care/cosmetics, we intend to utilize the regulatory expertise of others, whether they are consultants or commercial entities involved on collaborative development programs with the Company.
The following discussion relates to factors that may come into play when and if we have a commercially viable product in an area which requires regulatory approval. These products may be regulated by the European regulatory agencies, FDA, U.S. Department of Agriculture, certain state and local agencies, and/or comparable regulatory bodies in other countries (collectively, these agencies shall be referred to as the "Agencies"). Government regulation affects almost all aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping. The FDA and U.S. Department of Agriculture regulated products require some form of action by that agency before they can be marketed in the United States, and, after approval or clearance, the products must continue to comply with other FDA requirements applicable to marketed products. Both before and after approval or clearance, failure to comply with the FDA’s requirements can lead to significant penalties. Our proposed AAGP� products will require government regulatory approval as a biologic agent. Such regulatory approval will be granted only after the appropriate preclinical and clinical studies are conducted to confirm efficacy and safety.

Every company that manufactures biologic products or medical devices distributed in the United States must comply with the FDA’s Quality System Regulations. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation, and purchasing. Compliance with the Quality System Regulations is required before the FDA will approve an application. These requirements also apply to marketed products. Companies are also subject to other post-market and general requirements, including compliance with restrictions imposed on marketed products, compliance with promotional standards, record keeping, and reporting of certain adverse reactions or events. The FDA regularly inspects companies to determine compliance with the Quality System Regulations and other post-approval requirements. Failure to comply with statutory requirements and the FDA’s regulations can lead to substantial penalties, including monetary penalties, injunctions, product recalls, seizure of products, and criminal prosecution.

The Clinical Laboratory Improvement Act of 1988 prohibits laboratories from performing in vitro tests for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of, the health of human beings unless there is in effect for such laboratories a certificate issued by the U.S. Department of Health and Human Services applicable to the category of examination or procedure performed. Although a certificate is not required, we consider the applicability of the requirements of the Clinical Laboratory Improvement Act in the potential design and development of its products.

We are also subject to regulations in foreign countries governing products, human clinical trials and marketing, and may need to obtain approval or evaluations by international public health agencies, such as the World Health Organization, in order to sell products in certain countries. Approval processes vary from country to country, and the length of time required for approval or to obtain other clearances may in some cases be longer than that required for U.S. governmental approvals. The extent of potentially adverse governmental regulation affecting ProtoKinetix that might arise from future legislative or administrative action cannot be predicted.

Environmental Laws

To date, we have not encountered any costs relating to compliance with any environmental laws.

Plan of Operation

Our current operations are centered around our relationships with various research and development consultants who are conducting research on behalf of the company at discrete and established laboratories in various parts of the world. We intend to continue these efforts throughout 2012.

——————————————————————————–
Recent Developments
The Company is currently both negotiating and engaged with a number of companies under collaboration and material transfer agreements for the purposes of research and product development and out-licensing.

The companies are working in mutually exclusive areas.

Sales and Marketing

Although there are no revenues currently being generated through dales of AAGP, we are actively marketing AAGP though collaborations and applications development initiatives as described in the recent developments section above.

Results of Operations for the three months ended March 31, 2012 compared to March 31, 2011 are as follows:

We had $nil in net revenues for the period ending March 31, 2012.

Operating expenses from continuing operations and net loss were $66,359 for the three month period ending March 31, 2012 compared to $116,002 for the three months ending March 31, 2011. These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, specifically, research and development related expenses, and other general and administrative expenses. Significant changes from the prior three month period include;

Professional fees increased by $5,024 from $4,400 to $9,424 primarily as a result of a increase in activity with our legal council.

Consulting fees decreased by $51,089 from $67,589 to $16,500 as a result of fewer consulting agreements entered into by the company in 2012.

Liquidity and Capital Resources

At March 31, 2012, we had $17,527 in cash and $19,852 in total current assets. In the event that we need to raise additional capital, there can be no assurance that we will be able to raise capital from outside sources in sufficient amounts to fund our new business.

. . .

DENVER, May 15, 2012 /PRNewswire/ — DC Brands International, Inc., a publicly reporting company under the ticker symbol (OTC/HRDN), today announces that for the second consecutive year, it sponsored the 5K and 10K Armed Forces Run coordinated at Peterson Air Force Base in Colorado Springs. The 2012 Armed Forces Run took place this past weekend, and had simultaneously occurring runs at nine separate Air Force Bases around the world. H.A.R.D. Nutrition Functional Water Systems were provided to all the armed forces and civilians that participated in these runs at Air Bases here in the United States and around the globe.

The Company was very pleased with the turnout and interest in its H.A.R.D. Nutrition Functional Water Systems at this past weekend’s events at Peterson Air Force Base, which included a Health Fair on Friday, and the Armed Forces Run on Saturday. Despite the colder than normal temperatures, the crowds still lined up to get H.A.R.D. Nutrition Functional Waters, and were anxious to participate in the run.

H.A.R.D. Nutrition Functional Water Systems were distributed to all of our forces participating in this year’s Armed Forces Run at Air Bases in the Middle East of Bagram in Afghanistan, and Thumrait in Oman, as well as Thule in Greenland, two locations in Central and North Asia, a base in Africa, and two Air Bases in Alaska.

Dixon Marketing, a worldwide military marketing and sales agency now facilitates the distribution of H.A.R.D. Nutrition Functional Water Systems to the military systems.

To see photos of the 2012 Armed Forces Run and activities at Peterson Air Force Base, and the other Air Bases around the world, go to www.hardnutrition.com

VANCOUVER, May 15, 2012 /CNW/ – Plains Creek Phosphate Corporation ("Plains Creek", the "Company") (TSX‐V: PCP) announces the resignation of Mr. John Reynolds from the Board of Directors of the Company. As the Company has recently increased the size of the board with the addition of Mr. Kirill Zimin, Mr. Reynolds tendered his resignation to limit the number of his directorships and enable him to focus more on his other endeavors.

The Board wishes to thank Mr. Reynolds for his contributions to the development and success of the Company and wish him well in all his future ventures.

NI 43‐101 Compliant Technical Report:
The Company’s current technical report (the "Technical Report") for its Farim Phosphate Project prepared in accordance with National Instrument 43‐101 ("NI 43‐101") is entitled, "Technical Report on the Preliminary Economic Assessment of the Farim Phosphate Project, Guinea‐Bissau" dated effective February 10, 2010, and was filed under the Company’s profile on SEDAR at www.sedar.com on February 22, 2011. The Technical Report was prepared for the Company by John S. Warwick, B.Sc. (Hons) PIMMM, C.Eng., Eur.Ing. (Mining) of IMC Group Consulting Limited; Andre Lambert, B.Sc., MIMMM, EurGeol of IMC Group Consulting Limited; Alex Mitchell, MIMMM, C.Eng. of GBM Minerals Engineering Consultants Limited; and Michael Short, FIMMM, C.Eng. of GBM Minerals Engineering Consultants Limited, all of whom are independent Qualified Persons as defined under NI 43‐101.

About Plains Creek Phosphate Corporation:
Plains Creek Phosphate Corporation is a Canadian mining and exploration company focused on advancing iarim Phosphate Project located in Guinea‐Bissau, West Africa. The Project consists of a high‐quality development phosphate deposit containing a NI 43‐101 compliant measured phosphate resource of 69 million tonnes ("Mt") grading 29.9% P2O5, an indicated resource of 15 Mt grading 30.1% P2O5, and an inferred resource of 44 Mt grading 29.6% P2O5. The Project has a 25 year mining plan of 68 Mt phosphate grading 29.9% P2O5, as disclosed in the Company’s NI 43‐101 compliant Technical Report. The Company’s shares are listed on the TSX Venture Exchange under the trading symbol "PCP". For additional information, please visit us at www.plainscreek.com.

ON BEHALF OF THE BOARD

(signed) "Carson Phillips"
Carson Phillips
Vice‐President, Corporate Development and Director

What is $RACK??

What is Rackwise
Rackwise data center management software focuses on the hierarchy of needs within a data center organization. Our flagship software RACKWISE Data Center Manager (DCM) is a multi-layered software consisting of Data Center Essentials, Data Center Intelligence and Real-world Integration.

Data Center Essentials
Founded on the 5 key elements of data center management—Visualization, Documentation, Modeling, Analysis, Management—Data Center Essentials provides a strong base to build upon.

http://www.rackwise.com/software/data-center-essentials

Data Center Intelligence
Built on the foundation of Data Center Essentials, Data Center Intelligence provides the views and information needed to make data-driven decisions in a fully analyzed and graphical format. Financial Analysis is the pinnacle that completes the DCM Solution, providing you with the ability to model complex “What if” scenarios and report on their financial impact to the data center bottom line.

http://www.rackwise.com/software/dat…r-intelligence

Real World Integration
Integration to Data Center Management applications and data is bounded with an integration layer, Web services API. This allows RACKWISE DCM to integrate and participate with other software, data bases/CMDBs, and the process workflow of data center operations.

Data Center Optimization
Provides the functionality to optimize the data center by locating servers with low CPU utilization, recognize top power/space/heat consumption devices, and correlate those devices to the applications and business services they support. Decommission and commission devices according to most significant savings and ROI.

Determine the top power consuming racks – Determine server virtualization candidates by:

Low CPU utilization
High power consumption
High heat generation

Instantly calculate savings of decommission selected devices.

http://www.rackwise.com/software/dat…r-optimization

Data Center Business
Data Center Intelligence (DCI) provides additional insight into the data center in workings. This functionality provides those responsible planning and forecasting future data center needs the information necessary to meet those objectives simply and easily.

http://www.rackwise.com/software/data-center-business

Customer Implementation Flexibility
Rackwise provides a series of licensing models that allow you to choose the model that best suits your company needs:

Rackwise Data Center License – This is one time license fee for a perpetual software license with a yearly maintenance fee. You own, implement and operate the software on your site. Rackwise offers a series of fee-based services that include assessment, planning and implementation as well as training and knowledge transfer to assist for faster ROI. Additional fee based consulting services are available.

Rackwise Data Center Subscription – a one year on-site renewable subscription Rackwise OnDemand, a SaaS based model. Particularly appropriate for small and medium sized firms with data centers that do not exceed 100 racks. Rackwise is delivered as a service via the Cloud. No additional on-site hardware or software investment is required making this a more affordable model in some instances. Rackwise OnDemand is a pay-for-what-you-use purchase model.

Rackwise Services

Data Center Modeling
This is a Professional Service engagement for modeling new data centers or changes to data centers in Rackwise. This service is for customers who want expert assistance in getting a new or existing data center modeled in Rackwise as quickly and efficiently as possible. This service includes Data Reconciliation, Advanced Power modeling, Floorplan modeling and Implementation.

Data Reconciliation
Rackwise engineers will work with you to convert your existing rack and equipment data into the Rackwise import format. This service will produce a fully tested import sheet and the required additions to the Rackwise Equipment Library to accurately model your environment.

Advanced Power Modeling
This service will get the most out of the Advanced Power module for you. Rackwise engineers will work to accurately model your power environment in the Advanced Power module and provide training on the Advanced Power reports to fully utilize the software.

Rackwise Healthcheck
This service will bring your existing Rackwise implementation and models up to date with data, floorplans, rack elevations, training and all other items that will have Rackwise in a turnkey status for users. This service is intended to revitalize your Rackwise deployment and allow you to fully utilize the power of the Rackwise solution.

Project Management
This service provides general project management for Rackwise related projects. Professional Rackwise project managers will oversee the project, provide their expert help, and ensure that the engagement is a success. Projects will be scoped and an SOW will be provided.

Who’s behind OpenStack?

Founded by RACK Rackspace Hosting and NASA, OpenStack has grown to be a global software community of developers collaborating on a standard and massively scalable open source cloud operating system. Our mission is to enable any organization to create and offer cloud computing services running on standard hardware.

OpenStack Projects

OpenStack: The Open Source Cloud Operating System

OpenStack is a collaborative software project designed to create freely available code, badly needed standards, and common ground for the benefit of both cloud providers and cloud customers. OpenStack is currently these projects:

http://openstack.com/projects

Who is RACK/OpenStack for?

Institutions and service providers with physical hardware that they’d like to use for large-scale cloud deployments. (Additionally, companies who have specific requirements that prevent them from running in a public cloud.)

http://openstack.com

Rackwise Partners

Rackwise Clients

Business Wire – (Thursday, May 10)
Major West Coast Utility Embraces Rackwise® DCiM™ Solutions
http://finance.yahoo.com/news/major-…093000324.html

Business Wire – (Tuesday, May
Global Cruise and Travel Company Expands use of Rackwise® DCiM™ Solutions
http://finance.yahoo.com/news/global…143000277.html

Business Wire – (Thursday, April 26)
Richard Scannell Joins Rackwise, Inc. Industry Advisory Board
http://finance.yahoo.com/news/richar…093000332.html

Business Wire – (Monday, April 23)
U.S. Army Corps of Engineers Expands Deployment of Rackwise® DCiM™ Solutions
http://finance.yahoo.com/news/u-army…093000407.html

At Forbes – (Monday, April 16)
Why OpenStack will Become the First Open DevOps Project
http://www.forbes.com/sites/danwoods…rtner=yahootix

Business Wire – (Tuesday, April 3)
Steve Biondi Joins Rackwise, Inc. Industry Advisory Board
http://finance.yahoo.com/news/steve-…093000986.html

Contact Us:

North East:
Boston, MA
(978) 760 – 3180

North Central:
Chicago, IL
(630) 587 – 7839

South East:
Atlanta, GA
(770) 789 – 5622

South Central:
Dallas, TX
(214) 850 – 9700

West:
Los Angeles, CA

SHANGHAI, China, May 14, 2012 /PRNewswire/ – , May 14, 2012/CNW/ – Sunbelt International (www.sunbelt-inter.com) (SUNB.PK)

Sunbelt International is pleased to announce that a letter of intent has been signed to secure a multi-million dollar construction project in the central plateau region of Tanzania. This location in rural Tanzania has the optimal temperatures and wind speeds to produce the most power from Sunbelt International wind and solar turbines. A private Chinese Bank will provide financing for the Tanzania wind/solar project. The financing will provide engineering, construction and procurement services for Sunbelt International.

"The relationship we are building through this project in Tanzania will provide Sunbelt International great opportunities to expand projects globally, and operate on a larger scale," said Sunbelt International President Fang Soo Liu.

Testing facilities in Mongolia and northern Canada are proving to be successful ventures and continue to provide valuable feedback from the testing of high quality CE ISO certified wind turbines manufactured by Sunbelt International.

It is evident that the demand for wind and solar energy continues to grow. The Chinese government recently announced a progressive five-year plan that will target an annual growth in the use of wind and solar energy by over 1000% in the year 2015. With this substantial increase in demand, Sunbelt International will be in an excellent position to leverage future opportunities.

Sunbelt International Inc.
Fang Soo Liu President
fangsooliu@sunbeltenergy.net
info@sunbeltenergy.net
www.sunbeltenergy.net